IBT
International Biotechnology Trust Portfolio holdings
AUM
$297M
This Quarter Return
-0.44%
1 Year Return
+17.25%
3 Year Return
+11.14%
5 Year Return
+79.35%
10 Year Return
–
AUM
$256M
AUM Growth
+$256M
(-9.6%)
Cap. Flow
-$8.53M
Cap. Flow
% of AUM
-3.33%
Top 10 Holdings %
Top 10 Hldgs %
49.1%
Holding
75
New
10
Increased
14
Reduced
12
Closed
12
Top Buys
| 1 |
SHPG
Shire pic
SHPG
|
$10.1M |
| 2 |
Neurocrine Biosciences
NBIX
|
$9.7M |
| 3 |
ARRY
Array Biopharma Inc
ARRY
|
$6.1M |
| 4 |
Ionis Pharmaceuticals
IONS
|
$3.31M |
| 5 |
SAGE
Sage Therapeutics
SAGE
|
$3.06M |
Top Sells
| 1 |
Nektar Therapeutics
NKTR
|
$12.6M |
| 2 |
ENTL
Entellus Medical, Inc. Common Stock
ENTL
|
$8.33M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
$6.54M |
| 4 |
Amgen
AMGN
|
$6.28M |
| 5 |
Biogen
BIIB
|
$5.31M |
Sector Composition
| 1 | Healthcare | 94.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $18.3M | 7.15% | 205,522 +15,500 | +8% | +$1.38M |
|
|
SHPG
2
DELISTED
Shire pic
SHPG
| $14.8M | 5.77% | 99,000 +67,800 | +217% | +$10.1M |
|
|
ARRY
3
DELISTED
Array Biopharma Inc
ARRY
| $13.9M | 5.42% | 851,500 +374,000 | +78% | +$6.1M |
|
|
4
Neurocrine Biosciences
NBIX
$13.8B
| $12.8M | 4.98% | 154,000 +117,000 | +316% | +$9.7M |
|
|
5
Biogen
BIIB
$19.4B
| $12.5M | 4.87% | 45,608 -19,400 | -30% | -$5.31M |
|
6
Regeneron Pharmaceuticals
REGN
$61.5B
| $12.4M | 4.84% | 36,030 -4,800 | -12% | -$1.65M |
|
|
SAGE
7
DELISTED
Sage Therapeutics
SAGE
| $11.3M | 4.43% | 70,496 +19,000 | +37% | +$3.06M |
|
8
Vertex Pharmaceuticals
VRTX
$100B
| $11.1M | 4.34% | 68,222 -7,200 | -10% | -$1.17M |
|
9
Gilead Sciences
GILD
$140B
| $9.9M | 3.86% | 131,284 +8,500 | +7% | +$641K |
|
|
ADMS
10
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $8.83M | 3.45% | 370,000 +55,000 | +17% | +$1.31M |
|
11
Exelixis
EXEL
$10.1B
| $8.6M | 3.35% | 388,334 -22,000 | -5% | -$487K |
|
|
ALXN
12
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $8.07M | 3.15% | 72,441 | – | – |
|
|
STML
13
DELISTED
Stemline Therapeutics, Inc.
STML
| $7.52M | 2.93% | 492,930 | – | – |
|
14
Halozyme
HALO
$8.56B
| $7.03M | 2.74% | 358,633 +76,000 | +27% | +$1.49M |
|
15
Ligand Pharmaceuticals
LGND
$3.15B
| $6.94M | 2.71% | 42,000 +13,000 | +45% | +$2.15M |
|
16
Incyte
INCY
$16.5B
| $6.08M | 2.37% | 72,975 | – | – |
|
|
17
Ionis Pharmaceuticals
IONS
$6.79B
| $5.58M | 2.18% | 126,500 +75,000 | +146% | +$3.31M |
|
18
BioMarin Pharmaceuticals
BMRN
$11.2B
| $5.29M | 2.06% | 65,284 -3,100 | -5% | -$251K |
|
19
Alnylam Pharmaceuticals
ALNY
$58.5B
| $4.38M | 1.71% | 36,800 | – | – |
|
|
CLVS
20
DELISTED
Clovis Oncology, Inc.
CLVS
| $4.01M | 1.57% | 76,000 | – | – |
|
|
GTHX
21
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $3.81M | 1.49% | 103,000 +64,000 | +164% | +$2.37M |
|
|
BLUE
22
DELISTED
bluebird bio
BLUE
| $3.41M | 1.33% | 20,000 | – | – |
|
23
KalVista Pharmaceuticals
KALV
$678M
| $3.01M | 1.17% | 322,436 | – | – |
|
24
Agios Pharmaceuticals
AGIO
$2.19B
| $2.99M | 1.16% | 36,500 +16,500 | +83% | +$1.35M |
|
25
Jazz Pharmaceuticals
JAZZ
$7.75B
| $2.87M | 1.12% | +19,000 | New | +$2.87M |
|